News
5h
Zacks Investment Research on MSNTesla Losing Steam in Europe: What's Impeding Its Growth?Tesla’s TSLA car sales dropped significantly in several European countries in May, which marks the fifth straight month of ...
18h
The Cool Down on MSNTesla defies national slump with breakout success in key market: 'Actual car buyers ... make rational choices'Drivers are encouraged by this EV sales momentum. Tesla defies national slump with breakout success in key market: 'Actual ...
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results